A Phase Ib, Multi-Center, Open-Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination With Docetaxel or Gemcitabine in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2011
At a glance
- Drugs Docetaxel; Gemcitabine; PR 104
- Indications Solid tumours
- Focus Adverse reactions
- 01 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2007 New trial record.